Chronic Kidney Disease
Conditions
Interventions
Irbesartan 50-200mg/day from morning to bedtime administration
Irbesartan 50-200mg/day bfrom edtime to morning administration
Sponsors
Department of Nephrology, Nagoya university graduate school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients treated with irbesartan eight weeks or more at the informed consent acquisition (CKD:eGFR<60,proteinuria positive three months or more) 2)20 and over 3)Sex unquestioned 4)Inpatients and Outpatients 5)documented informed consent
Exclusion criteria
Exclusion criteria: 1)Pregant or possible pregnant patients 2)Patients with bilareral renal artery stenosis and patients with unilateral and renal artery stenosis 3)Nephrotic syndrome 4)Patients whose hepatic function was over 2 times higher than normal upper limit within eight weekss before the informed consent acquisition 5)Patients received hospitalizing by onset of cardiovascular disease, myocardial infarction, cerebral apoplexy, cardiac insufficiency within eight weeks before the informed consent acquisition 6)Allergic reaction to irbesartan 7)Judged inappropriate for this study by the physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Change of blood pressure (a:Office Blood pressure, b:Self-monitoring at home, c: ABPM) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.eGFR 2.Serum creatinine 3.Uric acid 4.Plasma renin activity 5.Plasma aldosterone 6.Urinary sodium concentration (daytime, sleeping time) 7. Albumin creatinine ratio of spot urine | — |
Countries
Japan
Contacts
Public ContactYoshinari Yasuda
Nagoya university graduate school of medicine Departmrnt of CKD initiatives
Outcome results
None listed